William Hope

List of Publications by Year
in descending order

191 papers	16,129 citations	30047 54 h-index	17090 122 g-index
195 all docs	195 docs citations	195 times ranked	13716 citing authors

#	Article	IF	Citations
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	2.9	4,375
2	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infectious Diseases, The, 2014, 14, 498-509.	4.6	745
3	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	6.3	695
4	Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. Journal of Antimicrobial Chemotherapy, 2014, 69, 1162-1176.	1.3	525
5	Laboratory diagnosis of invasive aspergillosis. Lancet Infectious Diseases, The, 2005, 5, 609-622.	4.6	432
6	EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clinical Microbiology and Infection, 2012, 18, E246-E247.	2.8	368
7	Liposomal Amphotericin B (AmBisomeÂ®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs, 2016, 76, 485-500.	4.9	332
8	Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncology, The, 2014, 15, e327-e340.	5.1	325
9	Tissue Penetration of Antifungal Agents. Clinical Microbiology Reviews, 2014, 27, 68-88.	5.7	319
10	Therapy for fungal diseases: opportunities and priorities. Trends in Microbiology, 2010, 18, 195-204.	3.5	268
11	ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. Clinical Microbiology and Infection, 2012, 18, 38-52.	2.8	264
12	Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 4782-4788.	1.4	192
13	F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12809-12814.	3.3	187
14	Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans. Antimicrobial Agents and Chemotherapy, 2004, 48, 4377-4386.	1.4	139
15	Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. Pediatric Infectious Disease Journal, 2009, 28, 412-415.	1.1	137
16	Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 136-153.	0.8	134
17	Therapeutic drug monitoring for triazoles. Current Opinion in Infectious Diseases, 2008, 21, 580-586.	1.3	128
18	Metallo-Î²-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	127

#	Article	IF	Citations
19	Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	124
20	Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis. Clinical Infectious Diseases, 2010, 51, 1383-1391.	2.9	123
21	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. New England Journal of Medicine, 2022, 386, 1109-1120.	13.9	119
22	Therapeutic drug monitoring of the Î²-lactam antibiotics: what is the evidence and which patients should we be using it for?: FigureÂ1.. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv201.	1.3	118
23	Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring. Clinical Infectious Diseases, 2009, 49, 928-930.	2.9	116
24	Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units. Pediatrics, 2014, 133, 236-242.	1.0	115
25	Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants. Clinical Pharmacology and Therapeutics, 2010, 87, 93-99.	2.3	114
26	Population Pharmacokinetics of Micafungin in Neonates and Young Infants. Antimicrobial Agents and Chemotherapy, 2010, 54, 2633-2637.	1.4	112
27	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. Journal of Clinical Investigation, 2019, 129, 999-1014.	3.9	112
28	Increase in prevalence of nosocomial non- Candida albicans candidaemia and the association of Candida krusei with fluconazole use. Journal of Hospital Infection, 2002, 50, 56-65.	1.4	110
29	EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clinical Microbiology and Infection, 2012, 18, E248-E250.	2.8	108
30	Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations. Antimicrobial Agents and Chemotherapy, 2012, 56, 2435-2442.	1.4	107
31	Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.. Drug Resistance Updates, 2013, 16, 81-95.	6.5	106
32	Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. Pediatric Infectious Disease Journal, 2011, 30, 375-378.	1.1	101
33	Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing. Antimicrobial Agents and Chemotherapy, 2007, 51, 3714-3719.	1.4	99
34	Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. Journal of Infectious Diseases, 2011, 203, 1324-1332.	1.9	96
35	Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis. Antimicrobial Agents and Chemotherapy, 2009, 53, 2382-2391.	1.4	90
36	Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 911-926.	1.5	90

#	Article	IF	Citations
37	Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. Journal of Antimicrobial Chemotherapy, 2017, 72, i12-i18.	1.3	90
38	Population Pharmacokinetics of Voriconazole in Adults. Antimicrobial Agents and Chemotherapy, 2012, 56, 526-531.	1.4	87
39	Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 5602-5610.	1.4	87
40	Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect. Antimicrobial Agents and Chemotherapy, 2009, 53, 3453-3461.	1.4	77
41	Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections. Antimicrobial Agents and Chemotherapy, 2012, 56, 4087-4094.	1.4	76
42	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	75
43	Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2013, 57, 5811-5819.	1.4	72
44	Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. Antimicrobial Agents and Chemotherapy, 2014, 58, 4094-4102.	1.4	72
45	Characterization and Comparison of Galactomannan Enzyme Immunoassay and Quantitative Real-Time PCR Assay for Detection of Aspergillus fumigatus in Bronchoalveolar Lavage Fluid from Experimental Invasive Pulmonary Aspergillosis. Journal of Clinical Microbiology, 2006, 44, 2475-2480.	1.8	71
46	Therapeutic drug monitoring of Î²-lactams for critically ill patients: unwarranted or essential?. International Journal of Antimicrobial Agents, 2010, 35, 419-420.	1.1	68
47	The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1â†'3)-Î²- <scp>d</scp> -Glucan, and Consequences of Delayed Antifungal Therapy. Antimicrobial Agents and Chemotherapy, 2010, 54, 4879-4886.	1.4	67
48	In Vitro Susceptibility of Aspergillus fumigatus to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole. Antimicrobial Agents and Chemotherapy, 2013, 57, 5778-5780.	1.4	67
49	EUCAST Technical Note on Voriconazole and Aspergillus spp.. Clinical Microbiology and Infection, 2013, 19, E278-E280.	2.8	66
50	Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates. Clinical Pharmacology and Therapeutics, 2011, 89, 702-707.	2.3	64
51	Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. Journal of Antimicrobial Chemotherapy, 2015, 70, 2854-2861.	1.3	64
52	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virusâ€"associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. Clinical Infectious Diseases, 2019, 68, 393-401.	2.9	62
53	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1495-1502.	1.3	60
54	Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. Current Opinion in Pharmacology, 2017, 36, 114-123.	1.7	59

#	Article	IF	Citations
55	Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 759-765.	1.5	56
56	How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. Diagnostic Microbiology and Infectious Disease, 2014, 79, 441-447.	0.8	56
57	Achieving Target Voriconazole Concentrations More Accurately in Children and Adolescents. Antimicrobial Agents and Chemotherapy, 2015, 59, 3090-3097.	1.4	56
58	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. Antimicrobial Agents and Chemotherapy, 2016, 60, 1183-1193.	1.4	55
59	Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Review of Molecular Diagnostics, 2007, 7, 21-32.	1.5	54
60	Cerebrospinal Fluid and Plasma (1â†'3)-Î²-<scp>d</scp>-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental HematogenousCandidaMeningoencephalitis. Antimicrobial Agents and Chemotherapy, 2008, 52, 4121-4129.	1.4	54
61	Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). Antimicrobial Agents and Chemotherapy, 2016, 60, 4568-4576.	1.4	54
62	EUCAST technical note on anidulafungin. Clinical Microbiology and Infection, 2011, 17, E18-E20.	2.8	53
63	Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints. Antimicrobial Agents and Chemotherapy, 2013, 57, 2793-2800.	1.4	52
64	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	52
65	Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	52
66	EUCAST Technical note on Amphotericin B. Clinical Microbiology and Infection, 2011, 17, E27-E29.	2.8	51
67	Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin. Antimicrobial Agents and Chemotherapy, 2011, 55, 3075-3083.	1.4	50
68	Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2010, 54, 3432-3441.	1.4	49
69	Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. Critical Care, 2016, 20, 343.	2.5	47
70	Pharmacodynamics of the Orotomides against Aspergillus fumigatus : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. MBio, 2017, 8, .	1.8	47
71	Optimising antimicrobial use in humans â€“ review of current evidence and an interdisciplinary consensus on key priorities for research. Lancet Regional Health - Europe, The, 2021, 7, 100161.	3.0	46
72	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. MBio, 2019, 10, .	1.8	44

#	Article	IF	Citations
73	Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clinical Microbiology and Infection, 2009, 15, 602-612.	2.8	43
74	Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients. Clinical Pharmacology and Therapeutics, 2014, 96, 438-448.	2.3	43
75	Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts. Antimicrobial Agents and Chemotherapy, 2011, 55, 4880-4887.	1.4	42
76	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. Antimicrobial Agents and Chemotherapy, 2016, 60, 1194-1201.	1.4	42
77	Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect. Antimicrobial Agents and Chemotherapy, 2006, 50, 3680-3688.	1.4	41
78	AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials, 2018, 19, 649.	0.7	41
79	Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. Journal of Antimicrobial Chemotherapy, 2019, 74, 2326-2334.	1.3	41
80	Optimizing management of invasive mould diseases. Journal of Antimicrobial Chemotherapy, 2011, 66, i45-i53.	1.3	40
81	Software for Dosage Individualization of Voriconazole for Immunocompromised Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 1888-1894.	1.4	40
82	Pharmacodynamics of teicoplanin against MRSA. Journal of Antimicrobial Chemotherapy, 2017, 72, 3382-3389.	1.3	40
83	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 757-763.	1.3	40
84	Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 2718-2726.	1.4	39
85	Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Clinical Infectious Diseases, 2017, 64, 1557-1563.	2.9	39
86	<scp>EUCAST</scp> Technical Note on Candida and micafungin, anidulafungin and fluconazole. Mycoses, 2014, 57, 377-379.	1.8	38
87	An invertebrate model to evaluate virulence in Aspergillus fumigatus: The role of azole resistance. Medical Mycology, 2014, 52, 311-319.	0.3	38
88	Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	38
89	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. Journal of Antimicrobial Chemotherapy, 2016, 71, 992-1002.	1.3	37
90	Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis. Antimicrobial Agents and Chemotherapy, 2007, 51, 285-295.	1.4	35

#	Article	IF	Citations
91	Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. Antimicrobial Agents and Chemotherapy, 2016, 60, 7340-7346.	1.4	35
92	Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. British Journal of Clinical Pharmacology, 2013, 75, 1381-1395.	1.1	34
93	Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	34
94	Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Critical Care, 2020, 24, 55.	2.5	34
95	Anidulafungin for Neonatal Hematogenous Candida Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach. Antimicrobial Agents and Chemotherapy, 2012, 56, 708-714.	1.4	33
96	Posaconazole: The Case for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2012, 34, 72-76.	1.0	32
97	A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. Pediatric Infectious Disease Journal, 2018, 37, 992-998.	1.1	32
98	Invasive aspergillosis: current and future challenges in diagnosis and therapy. Clinical Microbiology and Infection, 2004, 10, 2-4.	2.8	30
99	Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents. Antimicrobial Agents and Chemotherapy, 2015, 59, 905-913.	1.4	30
100	Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. Journal of Antimicrobial Chemotherapy, 2018, 73, 1340-1347.	1.3	30
101	Population Pharmacokinetics of Teicoplanin in Children. Antimicrobial Agents and Chemotherapy, 2014, 58, 6920-6927.	1.4	29
102	Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. Journal of Antimicrobial Chemotherapy, 2016, 71, 1885-1891.	1.3	29
103	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 2336-2342.	1.4	29
104	Cryptococcal meningoencephalitis: time for action. Lancet Infectious Diseases, The, 2021, 21, e259-e271.	4.6	29
105	Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality. Journal of Infection, 2012, 65, 350-356.	1.7	28
106	Delivering precision antimicrobial therapy through closed-loop control systems. Journal of Antimicrobial Chemotherapy, 2018, 73, 835-843.	1.3	28
107	Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in an In Vitro Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 5180-5185.	1.4	27
108	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	27

#	Article	IF	Citations
109	The pharmacology and clinical use of caspofungin. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 263-274.	1.5	26
110	Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens. Antimicrobial Agents and Chemotherapy, 2012, 56, 5303-5308.	1.4	26
111	Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 1411-1417.	1.4	26
112	Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2015, 59, 2735-2745.	1.4	26
113	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 2017, 72, 2342-2350.	1.3	26
114	Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	24
115	Gene Expression Profiles of Human Dendritic Cells Interacting with Aspergillus fumigatus in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface. PLoS ONE, 2014, 9, e98279.	1.1	24
116	Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3ÂDays of Therapy Is Equivalent to 14ÂDays. MBio, 2014, 5, e00725-13.	1.8	23
117	Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 278-287.	1.4	23
118	Invasive fungal infections. Clinical Medicine, 2013, 13, 507-510.	0.8	22
119	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. Trials, 2015, 16, 276.	0.7	22
120	An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. ELife, 2021, 10, .	2.8	22
121	Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing. Antimicrobial Agents and Chemotherapy, 2007, 51, 3760-3762.	1.4	21
122	The management ofCandidainfections in preterm neonates and the role of micafungin. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 24-27.	0.7	21
123	Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. Journal of Antimicrobial Chemotherapy, 2016, 71, 3168-3178.	1.3	21
124	A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.. Wellcome Open Research, 2019, 4, 8.	0.9	21
125	Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. Journal of Antimicrobial Chemotherapy, 2021, 76, 2252-2259.	1.3	21
126	Coâ€administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayedâ€released tablets in adult patients with haematological malignancies. British Journal of Clinical Pharmacology, 2018, 84, 2544-2550.	1.1	20

#	Article	IF	Citations
127	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	20
128	CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. Journal of Antimicrobial Chemotherapy, 2019, 74, 991-996.	1.3	19
129	Population pharmacokinetics and pharmacodynamics of fosfomycin in nonâ€“critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. Clinical Microbiology and Infection, 2018, 24, 1177-1183.	2.8	18
130	Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Paediatric Drugs, 2021, 23, 465-484.	1.3	18
131	EUCAST technical note on posaconazole*. Clinical Microbiology and Infection, 2011, 17, E16-E17.	2.8	17
132	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	1.8	17
133	Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 281-288.	1.4	16
134	Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Review of Clinical Pharmacology, 2016, 9, 887-897.	1.3	16
135	Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	16
136	Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. Journal of Antimicrobial Chemotherapy, 2016, 71, 3008-3019.	1.3	15
137	Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-Î²-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	15
138	First Dose in Neonates: Are Juvenile Mice, Adults and In Vitroâ€“In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole. Clinical Pharmacokinetics, 2014, 53, 1005-1018.	1.6	14
139	Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	14
140	Suboptimal Exposure to Antiâ€TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 449-457.	2.3	13
141	Pharmacokineticsâ€“pharmacodynamics of antifungal agents in the central nervous system. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 803-815.	1.5	13
142	Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	13
143	A PCR method for the identification of methicillin-resistant Staphylococcus aureus (MRSA) from screening swabs. Pathology, 2004, 36, 265-268.	0.3	12
144	Pharmacodynamics of Itraconazole against Aspergillus fumigatus in an In Vitro Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration. Antimicrobial Agents and Chemotherapy, 2012, 56, 4146-4153.	1.4	12

#	Article	IF	Citations
145	The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Drugs, 2017, 77, 941-950.	4.9	12
146	Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
147	Population Pharmacokinetics of Anidulafungin in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	12
148	Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	12
149	Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0029321.	1.4	12
150	Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. Current Opinion in Pharmacology, 2015, 24, 128-134.	1.7	11
151	Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. Therapeutic Drug Monitoring, 2018, 40, 315-321.	1.0	11
152	Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2019, 74, 1648-1655.	1.3	11
153	Pharmacodynamics of the Novel Metallo-Î²-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	11
154	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	11
155	Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. Journal of Antimicrobial Chemotherapy, 2022, 77, 711-718.	1.3	11
156	Urine D-arabinitol/L-arabinitol ratio in diagnosing Candida infection in patients with haematological malignancy and HIV infection. Diagnostic Microbiology and Infectious Disease, 2002, 42, 39-42.	0.8	10
157	Linezolid underexposure in a patient co-treated with venlafaxine. European Journal of Clinical Pharmacology, 2015, 71, 1285-1286.	0.8	10
158	Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 2234-2240.	1.3	10
159	Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	10
160	Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	10
161	Guidelines need controls. Clinical Microbiology and Infection, 2015, 21, 1043-1044.	2.8	9
162	Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	8

#	Article	IF	Citations
163	Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 1334-1343.	1.3	8
164	Aspergillus. , 2009, , 271-296.		6
165	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.. European Journal of Clinical Pharmacology, 2018, 74, 1449-1459.	0.8	6
166	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	6
167	Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	6
168	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. Journal of Antimicrobial Chemotherapy, 2022, 77, 466-473.	1.3	6
169	Optimising antifungal therapy for individual patients. Internal Medicine Journal, 2004, 34, 147-149.	0.5	5
170	Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. Journal of Infection, 2004, 49, 136-140.	1.7	5
171	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. Current Fungal Infection Reports, 2011, 5, 128-134.	0.9	5
172	Optimizing Micafungin Dosing in Children. Pediatric Infectious Disease Journal, 2012, 31, 1211-1212.	1.1	5
173	Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	5
174	Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. European Journal of Clinical Pharmacology, 2018, 74, 1091-1092.	0.8	5
175	Exposureâ€"Response Analysis of Micafungin in Neonatal Candidiasis. Pediatric Infectious Disease Journal, 2018, 37, 580-585.	1.1	5
176	Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	5
177	Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	5
178	Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. Antimicrobial Agents and Chemotherapy, 2021, 65, e0063621.	1.4	5
179	Combination therapy for carbapenemase-producing Entero-bacteriaceae: INCREMENT-al effect on resistance remains unclear. Lancet Infectious Diseases, The, 2017, 17, 899-900.	4.6	4
180	Precision Therapy for Invasive Fungal Diseases. Journal of Fungi (Basel, Switzerland), 2022, 8, 18.	1.5	4

#	Article	IF	Citations
181	Sequential infection with Nocardia farcinica and Cryptococcus neoformans var. gattii in an immunocompetent host. Journal of Infection, 2003, 47, 256-259.	1.7	3
182	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	2.9	3
183	Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. Mycoses, 2012, 55, 33-38.	1.8	2
184	1210A Phase 3, Randomized, Double-Blind, Non-inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients. Open Forum Infectious Diseases, 2014, 1, S36-S37.	0.4	2
185	(1â†'3)-Î²-D-Glucan in Cereobrospinal Fluid is a Surrogate Marker for Detection and Therapeutic Response of Hematogenous Candida Meningoencephalitis. International Journal of Infectious Diseases, 2008, 12, S48-S49.	1.5	1
186	Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. Journal of Infection, 2017, 74, 320-324.	1.7	1
187	Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, e0218121.	1.4	1
188	Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacteralesâ€"authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	1
189	Antifungal Pharmacokinetics and Pharmacodynamics. Methods in Pharmacology and Toxicology, 2016, , 369-383.	0.1	0
190	Antifungal Dosing Considerations for Term and Preterm Infants. , 2019, , 185-191.		0
191	Reply to Asempa et al., â€œThe Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Modelsâ€• Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	0